Post-licensure Deployment of Oral Cholera Vaccines: a Systematic Review

Overview

Journal Bull World Health Organ

Specialty Public Health

Date 2015 Jan 2

PMID 25552772

Citations 35

Authors

Stephen Martin

Anna Lena Lopez

Anna Bellos

Jacqueline Deen

Mohammad Ali

Kathryn Alberti

Dang Duc Anh

Alejandro Costa

Rebecca F Grais

Dominique Legros

Francisco J Luquero

Megan B Ghai

William Perea

David A Sack

Affiliations

Soon will be listed here.

Abstract

Objective: To describe and analyse the characteristics of oral cholera vaccination campaigns; including location, target population, logistics, vaccine coverage and delivery costs.

Methods: We searched PubMed, the World Health Organization (WHO) website and the Cochrane database with no date or language restrictions. We contacted public health personnel, experts in the field and in ministries of health and did targeted web searches.

Findings: A total of 33 documents were included in the analysis. One country, Viet Nam, incorporates oral cholera vaccination into its public health programme and has administered approximately 10.9 million vaccine doses between 1997 and 2012. In addition, over 3 million doses of the two WHO pre-qualified oral cholera vaccines have been administered in more than 16 campaigns around the world between 1997 and 2014. These campaigns have either been pre-emptive or reactive and have taken place under diverse conditions, such as in refugee camps or natural disasters. Estimated two-dose coverage ranged from 46 to 88% of the target population. Approximate delivery cost per fully immunized person ranged from 0.11-3.99 United States dollars.

Conclusion: Experience with oral cholera vaccination campaigns continues to increase. Public health officials may draw on this experience and conduct oral cholera vaccination campaigns more frequently.

Citing Articles

Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19.

Faucher B, Assab R, Roux J, Levy-Bruhl D, Tran Kiem C, Cauchemez S Nat Commun. 2022; 13(1):1414.

PMID: 35301289 PMC: 8931017. DOI: 10.1038/s41467-022-29015-y.

Foodborne Pathogenic Vibrios: Antimicrobial Resistance.

Dutta D, Kaushik A, Kumar D, Bag S Front Microbiol. 2021; 12:638331.

PMID: 34276582 PMC: 8278402. DOI: 10.3389/fmicb.2021.638331.

Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.

Ali M, Qadri F, Kim D, Islam M, Im J, Ahmmed F Lancet Infect Dis. 2021; 21(10):1407-1414.

PMID: 34146473 PMC: 9759785. DOI: 10.1016/S1473-3099(20)30781-7.

Licensed and Recommended Inactivated Oral CholeraVaccines: From Development to Innovative Deployment.

Deen J, Clemens J Trop Med Infect Dis. 2021; 6(1).

PMID: 33803390 PMC: 8005943. DOI: 10.3390/tropicalmed6010032.

Identifying and quantifying the factors associated with cholera-related death during the 2018 outbreak in Nigeria.

Elimian K, Musah A, Ochu C, Onwah S, Oyebanji O, Yennan S Pan Afr Med J. 2021; 37:368.

PMID: 33796181 PMC: 7992435. DOI: 10.11604/pamj.2020.37.368.20981.

References

Reyburn R, Deen J, Grais R, Bhattacharya S, Sur D, Lopez A . The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011; 5(1):e952. PMC: 3026767. DOI: 10.1371/journal.pntd.0000952. View

Anh D, Lopez A, Thiem V, Grahek S, Duong T, Park J . Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis. 2011; 5(1):e1006. PMC: 3026769. DOI: 10.1371/journal.pntd.0001006. View

Sinclair D, Abba K, Zaman K, Qadri F, Graves P . Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011; (3):CD008603. PMC: 6532691. DOI: 10.1002/14651858.CD008603.pub2. View

Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley A . Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011; 5(10):e1289. PMC: 3196468. DOI: 10.1371/journal.pntd.0001289. View

Clemens J, Shin S, Sur D, Nair G, Holmgren J . New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol. 2011; 8(12):701-10. DOI: 10.1038/nrgastro.2011.174. View

Ali M, Lopez A, You Y, Kim Y, Sah B, Maskery B . The global burden of cholera. Bull World Health Organ. 2012; 90(3):209-218A. PMC: 3314202. DOI: 10.2471/BLT.11.093427. View

Ivers L, Farmer P, Pape W . Oral cholera vaccine and integrated cholera control in Haiti. Lancet. 2012; 379(9831):2026-8. DOI: 10.1016/S0140-6736(12)60832-0. View

Hashim R, Khatib A, Enwere G, Park J, Reyburn R, Ali M . Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis. 2012; 6(7):e1743. PMC: 3404114. DOI: 10.1371/journal.pntd.0001743. View

Schaetti C, Weiss M, Ali S, Chaignat C, Khatib A, Reyburn R . Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012; 6(10):e1844. PMC: 3464297. DOI: 10.1371/journal.pntd.0001844. View

10.

Khatib A, Ali M, von Seidlein L, Kim D, Hashim R, Reyburn R . Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012; 12(11):837-44. DOI: 10.1016/S1473-3099(12)70196-2. View

11.

Martin S, Costa A, Perea W . Stockpiling oral cholera vaccine. Bull World Health Organ. 2012; 90(10):714. PMC: 3471062. DOI: 10.2471/BLT.12.112433. View

12.

Ciglenecki I, Sakoba K, Luquero F, Heile M, Itama C, Mengel M . Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 2013; 10(9):e1001512. PMC: 3769208. DOI: 10.1371/journal.pmed.1001512. View

13.

Ivers L, Teng J, Lascher J, Raymond M, Weigel J, Victor N . Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg. 2013; 89(4):617-624. PMC: 3795090. DOI: 10.4269/ajtmh.13-0183. View

14.

Rouzier V, Severe K, Juste M, Peck M, Perodin C, Severe P . Cholera vaccination in urban Haiti. Am J Trop Med Hyg. 2013; 89(4):671-681. PMC: 3795097. DOI: 10.4269/ajtmh.13-0171. View

15.

Luquero F, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M . First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis. 2013; 7(10):e2465. PMC: 3798604. DOI: 10.1371/journal.pntd.0002465. View

16.

Bhattacharya S, Sur D, Ali M, Kanungo S, You Y, Manna B . 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013; 13(12):1050-6. DOI: 10.1016/S1473-3099(13)70273-1. View

17.

Aibana O, Franke M, Franke M, Teng J, Teng J, Hilaire J . Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti. PLoS Negl Trop Dis. 2013; 7(11):e2576. PMC: 3837010. DOI: 10.1371/journal.pntd.0002576. View

18.

Khan I, Saha A, Chowdhury F, Khan A, Jasim Uddin M, Begum Y . Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013; 31(51):6058-64. DOI: 10.1016/j.vaccine.2013.10.021. View

19.

Kar S, Sah B, Patnaik B, Kim Y, Kerketta A, Shin S . Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis. 2014; 8(2):e2629. PMC: 3916257. DOI: 10.1371/journal.pntd.0002629. View

20.

. Oral cholera vaccine campaign among internally displaced persons in South Sudan. Wkly Epidemiol Rec. 2014; 89(20):214-20. View